Lifecore Biomedical Inc
Gesloten
SectorConsumenten defensie
4.2 2.94
Overzicht
Wijziging aandelenprijs
24u
Min
4.04
Max
4.16
Inkomsten | 9.8M -6.2M |
|---|---|
Verkoop | 11M 34M |
Winstmarge | -18.017 |
Werknemers | 382 |
Volgende Winsten | 10 dec 2026 |
|---|
Marktkapitalisatie | -20M 140M |
|---|---|
Vorige openingsprijs | 1.26 |
Vorige sluitingsprijs | 4.2 |
Nieuwssentiment
By Acuity
50%
50%
56 / 130 Rangschikking in Consumer defensive
Lifecore Biomedical Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Lifecore Biomedical Inc Prognose
Sentiment
By Acuity
56 / 130 Rangschikking in Consumenten defensie
Nieuwssentiment
Neutral
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Boven gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Lifecore Biomedical Inc
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.